Mi­rati and Am­gen un­wrap new KRAS tri­al da­ta, set­ting the stage for po­ten­tial com­bo treat­ments: #ES­MO23

MADRID — While suc­cess­ful in tar­get­ing one of the most elu­sive can­cer dri­vers, KRAS in­hibitors have failed to gen­er­ate huge up­take by them­selves. The com­pa­nies that have brought them to mar­ket are now un­veil­ing da­ta sug­gest­ing they could be used in com­bi­na­tion with oth­er drugs to make them more ef­fec­tive.

Over the week­end at the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy’s an­nu­al meet­ing, Am­gen and Mi­rati both shared da­ta from com­bi­na­tions of their KRAS drugs with oth­er med­i­cines that are used for col­orec­tal and lung can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER